Establish the rapid diagnosis system for chemosensitivity on head and neck cancer treatment

2017 Fiscal Year Final Research Report

• Project/Area Number: 26462625
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Aichi Medical University
• Principal Investigator: Ogawa Tetsuya 愛知医科大学, 医学部, 教授 (40334940)
• Co-Investigator(Kenkyū-buntansha): 吉川 和宏 愛知医科大学, 公私立大学の部局等, 特務教授 (60109759)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 抗がん薬感受性 / タンパク解析 / マイクロアレイ解析 / 機能解析

Outline of Final Research Achievements

Cisplation and 5FU are still mainstream chemotherapy drugs for head and neck carcinoma. We focused of protein and mRNA levels to gain higher precision result for identifying the chemoresistant factors.We used human HNSCC cell lines, cisplatin-sensitive, acquired cisplatin resistance, naturally cisplatin-resistant, and acquired 5-fluorouracil resistance. We performed proteomics analysis using iTRAQ and LC-ESI-MS/MS. We also did transcriptomics analysis using microarray. After integrating data, S100A2 a cisplatin-specific factor and BASP1 as multi-chemoresistance factor were identified. Functional analysis revealed expression S100A2 was reduced and recovered the cisplatin sensitivity.
This is a new frontier technique that will provide highly precise identifications as thinking of comprehensive analysis. Our findings indicate that these proteins can be used as criteria biomarkers for chemoresistance for head and neck cancer treatment.

Free Research Field

頭頸部癌